Epsilon M&A Deal Report - Heidelberg Pharma
Transaction Multiples for the Valuation of Private Companies
Wilex > Heidelberg Pharma
Announced Date : 03 November 2010
Type : Acquisition of Majority Stake
Deal Value : Yes
Acquirer : Wilex
Target: Heidelberg Pharma
Target Country: Germany
Sector of activity : Health, Pharmaceuticals & Biotechnology
Business Description :
> Heidelberg Pharma AG is a drug development company focused on cancer. > The company ...
Transaction multiples available
| EV/Sales | EV/Gross Profit | EV/EBITDA | EV/EBIT | Eq/PBT | P/E | Price to Book | |
|---|---|---|---|---|---|---|---|
| Historic | |||||||
| Current |
: Multiple available
n.s : Multiple calculated, but not significant
Rating **
Source: Epsilon Research / EMAT
Comparable Transactions
Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1245
Example of comparable transactions on EMAT (same sub-sector):
| Date | Acquirer | Target | Country | Multiples | See details |
|---|---|---|---|---|---|
| 01/12/2010 | Dechra Pharmaceuticals | Genitrix | United Kingdom | * | |
| 12/03/2007 | Smith & Nephew (S&N) | Plus Orthopedics Holding | Switzerland | *** |
Source: Epsilon Research / EMAT
This report is accessible on EMAT, the reference database for private company acquisition multiples
Example of EMAT Report : click here
View Complete ReportEpsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.
Sectors covered by our analysts
Studies & indices published by Epsilon Research Register to receive (free) publications updates
Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).
Sign up (free) to receive by e-mail updates on EMAT reports published on your preferred sector.
Subscribe to EMAT database
